FibroGen – $120 Million Shelf Takedown

Palo Alto – April 19, 2017 – Cooley advised FibroGen on its $120 million shelf takedown of 5,228,750 shares of common stock.

FibroGen, which is headquartered in San Francisco and trades on The NASDAQ Global Select Market as “FGEN,” is a research-based biopharmaceutical company using its expertise in connective tissue growth factor and hypoxia-inducible factor biology to discover, develop and commercialize novel therapeutics for serious unmet medical needs.

In 2014, Cooley advised FibroGen on its $167.7 million initial public offering.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Michael Tenta Partner, Palo Alto
Clark Chu Associate, Palo Alto
Erin Kravitz Associate, Palo Alto
Allison Pang Associate, Palo Alto
Natasha Leskovsek Partner, Washington, DC
Francis Wheeler Partner, Colorado